SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing trial design concerns and an ongoing clinical hold extended due to a potential adverse event in a related gene therapy utilizing the same AAV vector platform. The community is expressing significant disappointment over the rejection and its impact on RGNX's valuation, while also questioning the FDA's scrutiny of gene therapies and celebrating gains from short positions.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is experiencing a significant surge following its pre-announcement of substantially increased revenue guidance for the current quarter and strong fiscal year growth projections. This positive outlook is fueling investor excitement, with many anticipating further upside as the company, a key player in AI data center connectivity, continues to benefit from accelerating hyperscaler capital expenditures amidst ongoing discussions about its technological positioning.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is seeing significant bullish momentum after a short-seller retracted serious allegations against a major shareholder, driving a rebound and sparking community discussion around an imminent short squeeze and anticipated strong earnings.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to its latest earnings, where a revenue miss and softer forward guidance, particularly against a backdrop of ongoing automotive market softness, have disappointed investors. Community discussion centers on the company's valuation, perceived lack of growth beyond pure AI chip plays, and the broader impact of the EV sector slowdown.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant discussion as investors grapple with its recent price action ahead of its upcoming Q4 earnings report. Community sentiment is split between those who view its AI-powered lending model as massively undervalued given its profitability and prudent risk management, and others concerned by its conservative growth outlook and the broader fintech sector's current struggles.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after its stock plunged following the abrupt exits of its CFO and general counsel amidst an accounting review and delayed SEC filings, leading to a split in the community between those fearing significant financial issues and others who believe the drastic sell-off presents an overdone buying opportunity.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is actively discussed after its latest earnings surpassed expectations with record revenue and profitability, propelled by its AI initiatives including Uma. While many anticipate a short squeeze and highlight undervaluation in the evolving gig economy, others voice frustration over the stock's muted response and concerns about client growth in an AI-driven landscape.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is experiencing heightened attention as a new IPO amid extreme volatility, with community discussions largely focused on its low float potentially fueling a short squeeze.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending after recent earnings revealed strong EPS growth despite a revenue decline, driven by an expanding backlog and numerous new contracts in critical nuclear, defense, and space sectors. While some in the community express frustration over the stock's price action, many view these long-term contract wins and the company's perceived undervaluation as catalysts for substantial future growth.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a significant sell-off after providing weaker-than-expected revenue guidance for the upcoming quarter and fiscal year, despite reporting stronger-than-anticipated earnings and revenue growth. The community is actively debating whether this dip is an overreaction, weighing the company's strong customer retention and large cash reserves against intensifying market fears that AI tools could disrupt the traditional software business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Invus Global Management, Llc Purchases 1,538,462 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) Director Invus Global Management, Llc purchased 1,538,462 shares of the business's stock in a transaction dated Monday, February 2nd. The...

Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?

Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5% - Should You Sell?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5% - Time to Sell...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned an average rating of "Hold" from the six analysts that are presently covering the company, MarketBeat reports. One investment...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Sets New 52-Week High - Should You Buy...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Strong Trading Volume - What's Next?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Unusually-High Trading Volume - Here's Why...

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa (Sotagliflozin) for the Treatment of Heart Failure Viatris Expands Innovative Portfolio in...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.2% Higher - Time to Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 8.2% - Here's Why...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have earned an average rating of "Hold" from the seven research firms that are presently covering the firm, Marketbeat.com...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200-Day Moving Average - Time to Sell...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.20
Prev Close	$1.23
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	1.76
Avg. Volume	3.36M
PE Ratio	-6.49

52-Week High	$1.83
52-Week Low	$0.2836
Market Capitalization	$488.3M
EPS (Annual)	-$0.6262
Price to Book	3.72
Revenue Per Employee	$301,757.28
Enterprise Value/EBITDA	N/A

LXRX
Lexicon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXRX News

LXRXLexicon Pharmaceuticals Inc